Trastuzumab
3069
Summary
Trastuzumab is a monoclonal antibody against HER-2/neu, a tyrosine kinase receptor that is overexpressed in HER-2 positive breast cancer. As a result, trastuzumab is an effective treatment for HER-2 positive breast cancer. It can also be used in the treatment of gastric cancer. Finally, patient’s taking trastuzumab are at risk of developing cardiotoxicity.
Key Points
- Trastuzumab
- Mechanism
- Monoclonal antibody against HER-2/neu (c-erbB2)
- HER-2 is a tyrosine kinase receptor
- Trastuzumab helps with killing cancer cells that overexpress HER-2
- Inhibits HER-2 initiated cellular signaling and causes antibody-dependent cytotoxicity
- Monoclonal antibody against HER-2/neu (c-erbB2)
- Clinical use
- HER-2 positive breast cancer
- Gastric cancer
- Adverse effects
- Cardiotoxicity
- Mechanism